Other
NAC
0
Pipeline Programs↗
5
Active Trials↗
12
Companies Involved↗
NAC is an early-stage landscape with 0 programs across 12 companies. The most active players are Astellas, Regeneron, Merck & Co..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
44
clinical trials
Completed29 · 66%
Unknown status5 · 11%
Recruiting3 · 7%
Terminated2 · 5%
Withdrawn2 · 5%
Approved for marketing1 · 2%
Other2 · 5%
Clinical Trials
Trial Activity
44 trials
PanACEA - STEP2C -01
Recruiting·—·Phase 2·NCT05807399·390 enrolled
Real World Use of Lenacapavir, as an add-on to an Optimized Background Regimen in France
Recruiting·CCentre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida·N/A·NCT06799338·80 enrolled
A Study of GlcNAc on Tear Production in NGLY1-CDDG
Active, not recruiting·—·Phase 2·NCT05402345·18 enrolled
Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)
Completed·—·Phase 1·NCT02265224·48 enrolled
Use of N-Acetylcysteine (NAC) in Fingernail Biting
Completed·—·Phase 3·NCT01993849·23 enrolled
Solifenacin Flexible Dosing Study in Frequent Micturition Patients With and Without Urgency
Completed·—·Phase 4·NCT00979472·291 enrolled
Page 1 of 3
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)